Abstract |
Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.
|
Authors | Zelalem Temesgen, Judith E Feinberg |
Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 7
Issue 8
Pg. 759-65
(Aug 2006)
ISSN: 1472-4472 [Print] England |
PMID | 16955688
(Publication Type: Journal Article, Review)
|
Chemical References |
- Gene Products, gag
- Succinates
- Triterpenes
- bevirimat
|
Topics |
- Animals
- Clinical Trials, Phase II as Topic
- Drug Evaluation, Preclinical
- Gene Products, gag
(antagonists & inhibitors)
- HIV Infections
(drug therapy, metabolism)
- HIV-1
(metabolism)
- Humans
- Succinates
(adverse effects, pharmacokinetics, pharmacology, therapeutic use)
- Triterpenes
(adverse effects, pharmacokinetics, pharmacology, therapeutic use)
|